losartan-potassium and fedratinib

We report a Jak2V617F knockin mouse myeloproliferative neoplasm (MPN) model resembling human polycythemia vera (PV). The MPN is serially transplantable and we demonstrate that the hematopoietic stem cell (HSC) compartment has the unique capacity for disease initiation but does not have a significant selective competitive advantage over wild-type HSCs. In contrast, myeloid progenitor populations are expanded and skewed toward the erythroid lineage, but cannot transplant the disease. Treatment with a JAK2 kinase inhibitor ameliorated the MPN phenotype, but did not eliminate the disease-initiating population. These findings provide insights into the consequences of JAK2 activation on HSC differentiation and function and have the potential to inform therapeutic approaches to JAK2V617F-positive MPN.

Topics: Amino Acid Substitution; Animals; Antigens, CD; Bone Marrow; Bone Marrow Cells; Bone Marrow Transplantation; Cell Count; Cell Differentiation; Disease Models, Animal; Erythroid Precursor Cells; Erythropoietin; Gene Expression; Gene Expression Profiling; Hematocrit; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterozygote; Humans; Janus Kinase 2; Megakaryocyte Progenitor Cells; Megakaryocyte-Erythroid Progenitor Cells; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloid Progenitor Cells; Myeloproliferative Disorders; Polycythemia Vera; Protein Kinase Inhibitors; Pyrrolidines; Spleen; Sulfonamides; Survival Analysis